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The ten articles chosen for this year’s chapter reflect some key advances in the field of diabetes 
pregnancy, with large scale national and international collaborations pulling together to establish an 
evidence base for improving the health outcomes of pregnant women with diabetes and their 
children.  A major advance in the management of pre-gestational diabetes has been to collect and 
publish contemporary pregnancy outcome data in a timely fashion. The United Kingdom’s National 
Pregnancy in Diabetes (NPID) audit has published maternal characteristics, obstetric and neonatal 
outcome data on over 3,000 pregnancies (1). This large sample size allows for statistical comparison 
of serious adverse events and documents a sustained 2.5-fold reduction in the rate of stillbirth both 
in type 1 and in type 2 diabetes pregnancy. Whilst there is a small decline in stillbirth in the general 
maternity population the reduction in diabetes pregnancy is substantial and is most likely related to 
improvements in pregnancy preparation, fetal surveillance and earlier delivery. Unfortunately, there 
are no changes in rates of congenital anomaly or neonatal death. The audit also highlights 
suboptimal glucose control in type 1 diabetes and unacceptable clinic to clinic variation in the care of 
pregnant women with type 1 and type 2. The expectation is that by publishing these data there will 
be more collaborative working to ensure that services which are currently struggling are supported 
to improve. The audit highlights the need for new technologies to improve glucose control in late 
gestation type 1 diabetes pregnancy. The first automated insulin delivery, overnight closed-loop in 
pregnancy trial reported a 15% increase in overnight time-in-target compared to the best available 
comparator of sensor-augmented pump therapy (2). The lived experiences of women with diabetes 
who used closed-loop are reported separately and serve to remind us that as with all new 
treatments there are both benefits and burdens to be considered (3). Not surprisingly individuals 
weigh these up differently as some women with biomedical improvements were quite ambivalent 
about closed-loop while others with minimal objective improvement were far more positive about 
the impact of closed-loop on quality of life and reduced burden of diabetes self-management. 
Longer duration randomised trials of closed-loop compared to usual care with detailed biomedical 
and psychosocial outcomes are now required. Law et al urge us to look beyond traditional markers 
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of glucose control like HbA1c and estimated average glucose (eAG).  A novel pregnancy specific 
estimated average glucose (PeAG) is proposed, with the suggestion that aiming for a PeAG of 6.4-
6.7mmol/mol (4). Abell and colleagues remind us not to assume that increasing use of technology is 
necessarily associated with improved pregnancy outcomes and recommend larger scale high quality 
trials of insulin pumps in pregnancy (5).  The diabetes pregnancy community need to consider 
whether this is still feasible given the widespread use of pumps before and during pregnancy and/or 
whether trials of automated insulin delivery are more relevant.  
A landmark collaboration from the International Weight Management in Pregnancy (i-WIP) 
Collaborative Group provides the first individual patient data metaanalyses of diet and exercise 
interventions to reduce obstetric and neonatal risks in obese pregnant women (6). These data 
confirm that dietary and physical activity interventions are not harmful and work for women of all 
weights. Even modest weight loss, approximately 0.7kg is associated with reduced risk of caesarean 
delivery. Interventions based on increased physical activity may be particularly effective for reducing 
risk of gestational diabetes (GDM). Hodson et al suggest that in women with GDM, greater weight 
loss (0.4kg per week) can be safely achieved with a hypo-energetic diet of 1200kcal/day, with 50% 
reduced liver triacylglycerol and reduced need for additional insulin and/or metformin (7). As 
uncertainty remains about the use of glyburide and to a lesser extent metformin (8), a stronger 
evidence base for more rigorous well described dietary interventions in GDM is required. Likewise, 
for antenatal breastmilk expressing which seems intuitively sensible for management of neonatal 
hypoglycaemia (9). Whilst this does not seem to cause harm, larger trials of higher risk women are 
needed before this can be routinely recommended for all women with diabetes. Finally, a French 
group have reported the potential for good pregnancy outcomes in women with cystic fibrosis (CF). 
Furthermore, with improved treatment protocols, Cystic fibrosis related diabetes (CFRD) was not 




Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial 
clinic-to-clinic variations: a prospective nationwide study 
Murphy HR1,2, Bell R3, Cartwright C4, Curnow P4, Maresh M5, Morgan M6, Sylvester C4, Young B4 and 
Lewis-Barned N7 
1Norwich Medical School, Floor 2, University of East Anglia, Norwich NR4 7UQ, UK; 2Division of 
Women’s Health, North Wing, St Thomas’ Campus, Kings College London, London, UK; 3Institute of 
Health and Society, Newcastle University, Newcastle upon Tyne, UK; 4Clinical Audits & Registries 
Management Service, NHS Digital, Leeds, UK; 5Department of Obstetrics, St Mary’s Hospital, Central 
Manchester University Hospital NHS Foundation Trust, Manchester Academic Health Science Centre, 
Manchester, UK; 6Department of Obstetrics, Singleton Hospital, Abertawe Bro Morgannwg, 
Swansea, UK; 7Department of Diabetes and Endocrinology, Northumbria Healthcare NHS Foundation 
Trust, Northumberland, UK  
Diabetologia 60 (9); 1668-77 2017. 
Objectives: This prospective nationwide study examined outcomes of pregnant women with 
pregestational diabetes in England and Wales and compared changes over the decade since the 
2002-03 Confidential Enquiry in Maternal and Child Health (CEMACH).  
Methods: Data were collected as part of a national audit whereby maternity clinics are required to 
complete web-based data entry forms for all pregnant women with diabetes who had a pregnancy 
which ended in 2015. Outcomes of interest such as pregnancy preparation (5mg folic acid, first 
trimester HbA1c), perinatal morbidity (delivery prior to 37 weeks, large-for-gestational-age infants), 
congenital anomaly, stillbirth and neonatal death were collected and analysed.  
Results: A total of 3036 women from 155 maternity clinics were included. Most women had type 1 
diabetes (51%) or type 2 diabetes (46%) with other types of diabetes comprising 3% of women. The 
level of glycaemic control (HbA1c <6.5% or 48mmol/mol) achieved by women differed by clinic 
attended (median for women with type 1 diabetes 14.3% [interquartile range 7.7-22.2], type 2 
diabetes 37.0% [27.3-46.2]. In comparison to women with type 2 diabetes, women with type 1 
diabetes had more preterm births (39.7% versus 21.7%, p<0.001) and more large-for-gestational age 
infants (46.4% versus 23.9%, p<0.01). The rates of congenital anomaly and neonatal death were 
unchanged since 2002/2003. However, stillbirth rates following pregnancies complicated by both 
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type 1 diabetes (10.7 versus 25.8/1000 births, p=0.0012) and type 2 diabetes (10.5 versus 29.2/1000 
lives births, p=0.0091) were significantly lower in 2015 compared to 2002/2003.  
Conclusions: There is substantial clinic-to-clinic variation in proportion of women achieving target 
HbA1c and in rates of 5mg preconception folic acid supplementation. While there was no change in 
rates of congenital anomaly or neonatal death between 2002/2003 and 2015, there were 2.5 times 
less stillbirths. There were also improvements in the perinatal morbidity among newborn infants of 
mothers with type 2 diabetes, with lower rates of preterm birth and large-for-gestational age 
birthweight. 
Commentary: This study found a significant 2.5 fold reduction in the rate of stillbirth both in type 1 
and in type 2 diabetes. The reasons for this are unclear especially as neonatal death rates are 
unchanged. Furthermore, glycaemic control before and during pregnancy remains suboptimal 
especially among women with type 1 diabetes. There have been some improvements in glucose 
control and neonatal outcomes in type 2 diabetes. The substantial clinic-to-clinic variation suggests 
that there are opportunities for improvement in both type 1 and type 2 diabetes pregnancies.  
 
Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. 
Stewart ZA1, Wilinska ME1, Hartnell S2, Temple RC3, Rayman G6, Stanley KP4, Simmons D2, Law GR7, 
Scott EM7, Hovorka R1 and Murphy HR1,2,3,5 
1Wellcome Trust–Medical Research Council Institute of Metabolic Science, University of Cambridge, 
Cambridge, UK; 2Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS 
Foundation Trust, Cambridge, UK; 3Elsie Bertram Diabetes Centre University of East Anglia, Norwich, 
UK; 4Department of Obstetrics and Gynaecology, Norfolk and Norwich University Hospitals NHS 
Foundation Trust, University of East Anglia, Norwich, UK; 5Norwich Medical School, University of East 
Anglia, Norwich, UK; 6Ipswich Diabetes Centre, Ipswich Hospital NHS Trust, Ipswich, UK; 7Division of 
Epidemiology and Biostatistics, Leeds Institute of Cardiovascular and Metabolic Medicine, University 
of Leeds, Leeds, UK  
N Engl J Med 375(7): 644-654 2016 
Objective: Women with type 1 diabetes mellitus in pregnancy continue to have an increased risk of 
serious complications despite significant advances in diabetes care over time. Closed-loop insulin 
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delivery uses an insulin pump, continuous glucose monitor and a computer algorithm to adjust 
insulin delivery in real-time however, the data of its use in pregnancy are limited.  
Methods: This was a multicentre, open-label, randomized crossover study of pregnant women with 
type 1 diabetes. Women were randomized to 28 days of overnight closed-loop insulin delivery 
versus sensor augmented pump therapy followed by a 2-week washout period prior to crossing over. 
This was followed by a non-randomised extension period allowing participants to choose to use 
injections, an insulin pump, continuous glucose monitor or closed-loop, day-and-night until delivery.  
Results: In total, 16 women completed the study and were included in the analysis. The primary 
outcome, percentage of time overnight within the target glucose range, was significantly higher 
during the closed-loop phase compared to sensor-augmented pump phase (75% versus 60%, 95% CI 
[6.1, 24.3]). There was no significant difference in hypoglycaemia and no episodes of severe 
hypoglycaemia in the study period. Fourteen women chose to keep using closed-loop after the 
crossover period was complete. Women using day-and-night closed-loop achieved 68% time in 
target during pregnancy and a high percentage time in target (86%) when closed-loop was continued 
during labour and delivery.  
Conclusions: This study demonstrated that when compared to sensor-augmented pump therapy, 
closed-loop insulin delivery resulted in superior overnight glucose control without increasing 
hypoglycaemia. The continuation phase of this trial demonstrated the ability of the closed-loop 
system to perform day-and-night until 48 hours postpartum which included hospitalizations as well 
as labour and delivery.  
Commentary: This study of women with type 1 diabetes in pregnancy demonstrated the ability of 
closed-loop insulin delivery to improve time in target overnight when compared to sensor 
augmented pump therapy. The women included had a mean duration of diabetes of 23.6±7.2 years 
and many had a substantial history of pregnancy related complications. The continuation phase 
highlighted the adaptability of closed-loop during the changing demands of pregnancy: increasing 
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insulin resistance, changing glucose utilization, antenatal steroid administration, labour and delivery 
as well as the immediate postpartum period. Larger scale clinical trials are needed to study the 
closed-loop system in various populations as well as to assess the impact of closed-loop on obstetric 
and neonatal outcomes.   
Experiences of closed-loop insulin delivery among pregnant women with Type 1 diabetes 
Farrington C1, Stewart ZA2, Barnard K3, Hovorka R2 and Murphy HR2,4 
1Cambridge Centre for Health Services Research; 2Wellcome Trust–Medical Research Council 
Institute of Metabolic Science, University of Cambridge, Cambridge; 3Faculty of Health and Social 
Science, Bournemouth University, Bournemouth; 4Norwich Medical School, University of East Anglia, 
Norwich, UK  
Diabet Med. 2017 Jun 20. doi: 10.1111/dme.13406 
Objective: Closed-loop insulin delivery has shown potential as a valuable tool in the management of 
type 1 diabetes in pregnancy. However, the attitudes of women with diabetes towards this emerging 
technology had not been reported. This study aimed to evaluate the psychological aspects of the 
closed-loop in pregnancy.   
Methods: Participants in this analysis were part of an open-label, randomized, crossover study 
comparing closed-loop insulin delivery to sensor-augmented pump therapy in women with type 1 
diabetes pregnancy. Mixed methods were used to analyse participant questionnaires and semi-
structured interviews. 
Results: A total of 16 participants were included in this study. Of the 16 women who were 
randomized, 14 chose to continue the closed-loop system after the crossover was complete. The 
questionnaire and interview data were consistent, both highlighting perceived benefits such as 
improved glucose control, feeling more “normal” and ‘time off’ from diabetes. Interviews also 
revealed themes of excitement and empowerment regarding the potential of closed-loop for future 
management of diabetes. Many women identified drawbacks regarding closed-loop therapy such as 
spending more time thinking about diabetes, the bulkiness of the system, device challenges and 
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possible ‘deskilling’ regarding alertness for symptoms of hyper and hypoglycaemia. Women’s 
perception of glucose control and directly measured CGM time in target sometimes differed.  
Conclusions: This study describes the benefits and burdens experienced by women using closed-loop 
in type 1 diabetes pregnancy.   
Commentary: Closed-loop is on the forefront of the management of diabetes in pregnancy. This 
study explores the psychological aspects of the closed-loop system on women using it as part of a 
randomized study. Not surprisingly, participants noted both benefits and burdens associated with 
using the system. Some participants also revealed feelings of excitement and empowerment, a 
promising sentiment for patients with diabetes. While the technology is likely to improve in terms of 
its cumbersomeness, the concern for potential ‘deskilling’ with regards daily diabetes self-
management will need to be further considered as studies with the artificial pancreas advance.    
Translating HbA1c measurements into estimated average glucose values in pregnant 
women with diabetes 
Law GR1, Gilthorpe MS2, Secher AL3, Temple R4, Bilous R5, Mathiesen ER3, Murphy HR 4,6 and Scott 
EM2  
1School of Health and Social Care, University of Lincoln, Lincoln, UK; 2Division of Epidemiology and 
Biostatistics, University of Leeds, Leeds, UK; 3Institute for Clinical Medicine, University of 
Copenhagen, Copenhagen, Denmark; 4Elsie Bertram Diabetes Centre, Norfolk and Norwich 
University Hospital NHS Trust, Norwich, UK; 5Newcastle University Medicine Malaysia, Johor, 
Malaysia; 6Norwich Medical School, University of East Anglia, Norwich, UK  
Diabetologia 60(4): 618-624 2016 
Objective: Continuous glucose monitoring has been used to assess the relationship between average 
glucose and HbA1c in various studies outside of pregnancy. Given the various physiologic changes 
throughout pregnancy and the known limitations of HbA1c in this population, estimates outside of 
pregnancy may not be accurate in pregnant women. This study sought to define the relationship 
between estimated average glucose (eAG) and HbA1c throughout pregnancy in women with type 1 
and type 2 diabetes mellitus.  
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Methods: Data from two previous randomized controlled trials examining continuous glucose 
monitoring (CGM) in women with type 1 and type 2 diabetes in pregnancy were used for this study. 
The average glucose, defined as the mean glucose values from CGM for a 5 to 7-day period, was 
compared to HbA1c values taken within 1 week. Regression modeling was used to determine this 
relationship.  
Results: Data from 117 patients (89 with type 1 diabetes and 28 with type 2 diabetes) were included. 
An analysis of 688 CGM profiles and 688 HbA1c’s was performed. Using CGM data, the authors 
calculated an eAG at various times in pregnancy using the formula: “glucose (mmol/L) = 6.78 + [0.43 
x (HbA1c [%] – 6.3)] + 0.004 x (gestation [weeks] – 2)] – 0.001 x (gestation [weeks]2 – 528]”. They 
found that in pregnancy, a 1% difference in HbA1c is equivalent to 0.67 mmol/L in average glucose 
levels. More specifically, HbA1c during pregnancy is associated with lower estimated average 
glucoses than outside of pregnancy. This difference between the pregnancy specific and non-
pregnancy average glucoses increased with increasing HbA1c values.  
Conclusions: The drop in HbA1c in pregnancy represents a smaller change in average glucose than 
the equivalent drop outside of pregnancy 
Commentary: HbA1c plays a central role in the assessment of glucose control in patients with 
diabetes in pregnancy. While studies have demonstrated an association with HbA1c and various 
pregnancy outcome data, HbA1c has the potential to be unreliable due to the dynamic physiology of 
pregnancy. The authors note some limitations such as the narrow patient population and the 
different methods of determining average glucose from the comparative study outside of pregnancy. 
However, overall this study demonstrates a difference between the relationship between average 
glucose and HbA1c and offers clinicians a practical method of assessing glucose based on aiming for 
average glucose levels of 6.4-6.7mmol/L. 
Pregnancy Outcomes and Insulin Requirements in Women with Type 1 Diabetes Treated with 
Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections: Cohort Study 
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Abell SK1,2, Suen M2, Pease A2, Boyle JA1,3, Soldatos G1,2, Regan J3, Wallace EM3,4 and Teede HJ1,2 
1Monash Centre for Health Research and Implementation, School of Public Health and Preventive 
Medicine, Monash University, Clayton, Australia; 2Diabetes and Vascular Medicine Unit, Monash 
Health, Clayton, Australia; 3Monash Women’s Services, Monash Health, Department of Obstetrics 
and Gynecology, Clayton, Australia; 4The Ritchie Centre, Department of Obstetrics and Gynaecology, 
Monash University, Clayton, Australia.  
Diabetes Technol Ther 19(5): 280-287 
Objectives: The importance of achieving tight glycaemic control throughout pregnancy in women 
with type 1 diabetes is well established. This study examined glycaemic control and pregnancy 
outcomes in women with type 1 diabetes using continuous subcutaneous insulin infusion (CSII) 
versus multiple daily injections (MDI).  
Methods: This was retrospective cohort study of women with type 1 diabetes receiving care as part 
of a public health service in Australia. It included women with singleton pregnancies and births after 
20 weeks gestation. Data were collected by chart review and from a Birthing Outcomes System 
database.  
Results: In total, 40 pregnancies using CSII and 127 using MDI were included in the analysis. There 
was no statistically significant difference in baseline diabetes characteristic between the two groups. 
There was no evidence of a difference in glycaemic control achieved (as measured by HbA1c), or 
obstetrical outcomes between women using CSII versus MDI. When compared to women using MDI, 
women with CSII were prescribed less insulin preconception and throughout pregnancy as well as a 
smaller percent change of insulin requirements (in units/kg) in early compared to late pregnancy 
(40% versus 52%).  
Conclusions: In this cohort of pregnant women with type 1 diabetes, there were no significant 
differences in glycaemic control or obstetrical outcomes treatment with CSII versus MDI.  
Commentary: The cohort study adds to the literature on CSII versus MDI in the management of type 
1 diabetes in pregnancy. This study had a small sample size and was not powered to show a 
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difference in glycaemic control and obstetrical outcomes. In contrast, Kallas-Koeman et al. 
demonstrated a significantly lower HbA1c throughout pregnancy in their larger study of 113 
pregnancies managed with CSII versus 218 pregnancies with MDI (11). They noted a higher 
proportion of large-for-gestational-age neonates in the CSII group (55.0% versus 39.2%, p=0.007) but 
no difference in other obstetrical outcomes. The literature examining the effect of CSII is made up 
primarily of cohort studies which are subject to bias, i.e. women who are on pumps may be different 
from women on MDI. With the introduction of closed-loop, we may not see high quality randomised 
trials of CSII and MDI in pregnancy, although these are needed to evaluate the safety and efficacy of 
pumps in pregnancy.  
Effect of diet and physical activity based interventions in pregnancy on gestational weight 
gain and pregnancy outcomes: meta-analysis of individual participant data from 
randomised trials 
International Weight Management in Pregnancy (i-WIP) Collaborative Group 
BMJ. 2017 Jul 19;358:j3119. doi: 10.1136/bmj.j3119 
Objectives: Approximately one in two women of reproductive years are now overweight or obese 
with short and longer-term health implications for both mother and child. The impact of dietary and 
physical activity (PA) interventions starting during pregnancy have generally being disappointing. The 
aim of this meta-analysis of individual participant’s data (IPD) was to synthesise the published 
evidence and work out the effects of diet and PA on maternal gestational weight gain and 
maternal/infant health outcomes.  
Methods: IPD was obtained from 36 randomised trials involving >12,500 women in 16 countries. This 
included 22 studies from Europe, 4 each from USA, Australia, Brazil and 1 each from Egypt and Iran. 
23 studies included women of any weight, 6 included overweight and obese women and 7 included 
only obese women. The interventions were mainly based on diet (n=4), PA (n=16) or a combination 
of diet and lifestyle (n=15). Women with gestational diabetes (GDM) and known hypertensive 
disorders were excluded. The primary outcome was Gestational weight gain (GWG), defined as the 
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difference between maternal weight at booking and the last weight before delivery. Key secondary 
outcomes were GDM, hypertensive disorders, preterm and caesarean delivery (mothers) and 
stillbirth, large or small for gestational age and neonatal intensive care unit  (NICU) admission 
(infants). The overall effects of interventions were examined for composite and for individual 
maternal and infant outcomes.  
Results: The women were mostly (>80%) white, 45% primiparous, 40% obese and 40% sedentary. 
Approximately 50% were classified as of high socioeconomic status. Data for approximately 50% 
eligible women was not available. The largest data were available for large for gestational age (LGA) 
with 34 studies (>12,000 women), with similarly high numbers (<11,000) for preterm delivery, small 
for gestational age (SGA) and caesarean section. For GWG, hypertensive disorders of pregnancy and 
GDM there were data from approximately 9,500 women. Slightly smaller datasets were available for 
the maternal and infant composite outcomes (8,800 and 7,900 respectively). Both diet and PA 
interventions were effective in reducing GWG by approximately 0.7kg, which did not differ according 
to maternal normal weight, overweight or obesity. Likewise there was no evidence of differential 
effects for maternal baseline demographic characteristics such as age, parity, ethnicity and pre-
existing medical conditions. There was also a significant reduction in caesarean section with 
summary estimates that favoured the interventions for both the maternal and infant composite 
outcomes, but these did not reach statistical significance. The reduction in other individual 
outcomes such as GDM, preterm delivery were also not statistically significant. When study level 
data from non-IPD studies were meta-analysed with IPD, there was stronger evidence for GDM 
reduction (59 studies in 16885 women). Interventions based on PA showed a reduction in GDM in 
both IPD and combined IPD and non-IPD meta-analysis (OR 0.67 and 0.66). Likewise for the impact of 
PA on reduction in caesarean section and hypertensive disorders the combined IPD and non-IPD 
meta-analysis suggested stronger evidence of benefit with reductions by 17% for caesarean section 
and 32% for hypertensive disorders. For diet only interventions there was a strong effect for 
reduction in preterm delivery in both the IPD alone and the combined IPD and non-IPD meta-
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analysis, but these analyses were limited to 4 and 7 studies with approximately 1300 and 1700 
women respectively.  
Conclusions: This large collaborative IPD meta-analysis confirms that diet and PA interventions are 
effective for reducing GWG in all women, and did not vary according to maternal weight. However 
the effect is clinically modest (0.7kg) and impact on postpartum weight retention and longer term 
health outcomes is unknown. The only individual outcome impacted was reduced odds of delivery 
by caesarean section. The addition of study level data from non-IPD studies showed benefit for 
reduction in GDM, in particular for PA based interventions. The lack of harm (for example no 
increase in preterm delivery or small for gestational age) should provide reassurance to mothers and 
clinicians that diet and PA are safe during pregnancy.  
Comment: This large collaborative undertaking is the first to evaluate the differential effects of diet 
and PA on a range of clinically important outcomes. This provided statistical power for estimating 
covariate interactions and adjusting for maternal age, weight and important baseline characteristics. 
Because of the speed of new publications in this area, it was not possible to perform IPD meta- 
analysis for all published trials. They therefore also reported on outcomes from combined IPD and 
non-IPD meta-analysis. 
Liver triacylglycerol content and gestational diabetes: effects of moderate energy 
restriction. 
Hodson K1,2,3, Dalla Man C4, Smith FE5,6, Barnes A7, McParlin C5,8, Cobelli C4, Robson SC5,8, Araújo-
Soares V7, Taylor R5,6,8. 
1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. 2Royal Victoria 
Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. 
3Newcastle Magnetic Resonance Centre, Newcastle University Campus for Ageing and Vitality, 
Newcastle upon Tyne, NE4 5PL, UK .4Department of Information Engineering, University of Padova, 
Padova, Italy.5Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.  
6Newcastle Magnetic Resonance Centre, Newcastle University Campus for Ageing and Vitality, 
Newcastle upon Tyne, NE4 5PL, UK. 7Institute of Health and Society, Newcastle University, Newcastle 
upon Tyne, UK.8Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, 
Newcastle upon Tyne, UK. 
Diabetologia. 2017 Feb;60(2):306-313 
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Objectives: Energy restriction, while effective for improving glucose control and liver triacylglycerol 
in type 2 diabetes, remains controversial during late pregnancy. The aim of this Weight Loss Looking 
for Mother and Baby Better Outcomes (WELLBABE) study was to quantify the impact of a 4-week 
calorie restricted diet in women with GDM. 
Methods: 16 women with GDM (gestational age 27±3.3 weeks) were recruited to a 4-week hypo-
energetic diet (1200kcal/day) with a magnetic resonance spectroscopy (MRS) scan and standardised 
meal test performed before and after the intervention and between 12-28 weeks post-partum. The 
dietary intervention was delivered by trained research dietitians (50% carbohydrate, 25% protein, 25 
% fat) supported by portion size cups and a smartphone application (MyFitnessPal). After the 4-week 
dietary intervention women were recommended to continue on approximately 1500kcal/day. The 
data from 28 matched comparators with GDM were compared with those of women in the 
intervention group.  
Results: Women in the intervention group (age 31.5, weight 93.1kg, BMI 34.6) lost 0.4kg/week or 
1.6±1.7kg in total compared to weight gain of 0.3kg/week or 1.4±1.2kg in the comparator group. Six 
women lost >2kg, five women lost 0.3-1.2kg and three had a small weight gain (<0.5kg). Two women 
dropped out. The mean liver triacylglycerol was halved (3.7 to 1.8%) after 4-weeks of dietary 
restriction and returned to baseline by 12-28 weeks postpartum. Fasting plasma glucose, post-meal 
glucose, fasting insulin and C-peptide and markers of insulin resistance were unchanged pre and 
post intervention. Lipid levels and fasting NEFA were unchanged. Insulin resistance was reduced 
post-partum. The numbers of women requiring treatment were 0 for insulin and 2 for metformin 
compared to 6 and 8 respectively in the comparator group. Glucose control and maternal fetal 
outcomes did not differ between the two groups.  
Conclusion: Dietary intervention was well tolerated by women, and associated with 0.4kg weight 
loss per week and a 50% reduction in liver triacylglycerol. The finding that liver triacylglycerol levels 
were normal and not elevated as suggested in previous pregnancy literature was unexpected given 
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the central role of lipid metabolism in the pathogenesis of GDM and type 2 diabetes. The authors 
speculate that liver triacylglycerol levels decrease reciprocally with elevated plasma triacylglycerol 
levels in GDM pregnancy. 
Comment: The study provides further reassurance for women and clinicians regarding the potential 
for benefit from a more aggressive hypo-energetic dietary intervention. In particular, it suggests that 
an effective dietary intervention reduces the need for additional pharmacotherapy with insulin 
and/or metformin. Larger randomised clinical trials of a more sustained hypo-energetic diet in 
women with GDM are required.  
Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes 
Mellitus: A Randomized Controlled Study 
Nachum Z1,2, Zafran N1,2, Salim R1,2 Hissin N1, Hasanein J3, Gam Ze Letova Y1, Suleiman A1 and Yefet E1 
1Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel; 2Rappaport Faculty 
of Medicine, Technion, Haifa, Israel; 3Department of Neonatology, Emek Medical Center, Afula, Israel  
Diabetes Care 40(3): 332-337 
Objective: The mainstay of treatment of gestational diabetes mellitus is lifestyle modification 
however, often pharmacotherapy is needed to achieve target glucose control. The aim of this study 
is to assess the use of glyburide versus metformin versus glyburide plus metformin in the 
management of gestational diabetes.     
Methods: This was on open-label, single centre, randomized controlled trial women with gestational 
diabetes diagnosed at 13-33 weeks gestation. Women were initially randomized to either glyburide 
2.5-5.0 mg/day versus metformin 850-2550 mg/day. If glycaemic targets were not achieved on 
monotherapy, the alternative medication was started. Patients who experienced adverse events 
were placed on the alternative medication. If glycaemic targets were not reached on two drug 
therapy, patients were started on insulin. The primary outcomes were inability to achieve glycaemic 
targets and glycaemic control on the medication to which the patient was originally randomized.   
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Results: This study randomized 104 women to glyburide (53 women) or metformin (51 women). Of 
the participants randomized to receive glyburide, 12 (23%) required the addition of metformin and 6 
(11%) were switched to metformin because of an adverse effect. Of the participants randomized to 
metformin, 14 (28%) required the addition of glyburide and 1 (2%) were switched to glyburide 
because of an adverse effect. There was no statistically significant difference in adverse effects 
between glyburide and metformin (p=0.11). A total of 11 patients required insulin therapy: four for 
adverse effects to oral medication and seven due to inability to meet glycaemic targets. There was 
no significant difference in pregnancies outcomes reported.  
Conclusions: Glyburide and metformin perform similarly in terms of the treatment and adverse 
effects of gestational diabetes diagnosed between 13 and 33 weeks gestation.  
Commentary: This trial is too small to provide adequate reassurance regarding use of glyburide. 
Both metformin and glyburide have been shown to cross the placenta. In their large trial of 
metformin versus insulin in the treatment of gestational diabetes, Rowan et al. did not demonstrate 
a concern for adverse events with metformin (12). However, a large observational cohort suggested 
glyburide may be associated with increased neonatal complications when compared to insulin (13).  
Advising women with diabetes in pregnancy to express breastmilk in late pregnancy (Diabetes and 
Antenatal Milk Expressing [DAME]): a multicentre, unblinded, randomised controlled trial 
Forster DA1,2, Moorhead AM1,2, Jacobs SE 2,3,4, Davis PG2, Walker SP3,5, McEgan KM5, Opie GF3,5, 
Donath SM6, Gold L7, McNamara C5, Aylward A2, East C8, Ford R2, Amir LH1,2 
1 Judith Lumley Centre, School of Nursing and Midwifery , La Trobe University, Melbourne, VIC, 
Australia; 2Royal Women's Hospital, Parkville, VIC, Australia; 3Department of Obstetrics and 
Gynaecology, University of Melbourne, VIC, Australia; 4Clinical Sciences, Murdoch Childrens 
Research Institute, Parkville, VIC, Australia; 5Mercy Hospital for Women, Heidelberg, VIC, Australia. 
6Clinical Epidemiology and Biostatistics Unit, Murdoch Childrens Research Institute, Parkville, VIC, 
Australia. 7School of Health and Social Development, Deakin University, Geelong, VIC, Australia. 
8School of Nursing and Midwifery, Monash University and Monash Health, Clayton, VIC, Australia  
Lancet Volume 389, Issue 10085, 3–9 June 2017, Pages 2204-2213 
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Objectives: To determine the safety and efficacy of antenatal milk expressing in women with 
diabetes. The rationale is that expressing and storing colostrum during late pregnancy would provide 
breastmilk for infants who are admitted to neonatal intensive care units (NICU) after delivery and 
thus facilitate exclusive breast-feeding during the early neonatal period. It has also been suggested 
that colostrum may be more effective for stabilising neonatal glucose levels than formula milk.  
Methods: An open-label, multicentre randomised controlled trial of 635 women with diabetes in six 
Australian maternity hospitals. Women with a singleton pregnancy were randomised between 34-37 
weeks gestation to hand expressing of breastmilk for up to 10 minutes twice daily from 36 weeks 
gestation or to standard antenatal care. Women with evident fetal growth restriction or fetal growth 
acceleration (ultrasound estimated fetal weight ≥95th percentile with abdominal circumference 
>97th centile, polyhydramnios), and breech presentation were excluded. Women were taught how 
to express while having cardiotocography (CTG) surveillance and asked to monitor their capillary 
glucose levels on the first three occasions. The primary outcome was the proportion of infants 
admitted to the NICU. Key secondary outcomes were gestational age at birth, neonatal 
hypoglycaemia defined as < 2·6 mmol/L before feeding and exclusive breastmilk feeding.  
Results: Most women (>90%) had gestational diabetes (GDM) and approximately half were insulin 
treated. Metformin was not commonly used (<1%). Only small numbers of women with pre-
gestational diabetes were included (3-4% with type 1 and type 2 diabetes). Approximately half were 
overweight or obese and just over half were primiparous (57.5%). During the 18 days from 
randomisation until delivery, >40% of women in the intervention group expressed more than 20 
times with 25% expressing 6-19 times. The mean volume of colostrum obtained was 5.5ml. A small 
number of control group women (<10%) reported some breastmilk expressing before delivery. There 
were no between-group differences in the proportion of infants admitted to NICU (15 vs 14%), 
gestational age at delivery (38.6 vs 38.7 weeks) or reasons for NICU (neonatal hypoglycaemia 42 vs 
36%, infection 42 vs 41% and respiratory distress (27 vs 23%). The proportion of infants requiring iv 
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dextrose also did not differ (11 vs 9%). The rates of exclusive breast feeding for the intervention vs 
control group were as follows; 69 vs 60% day 1, 57 vs 49% day 7 and 60 vs 55% at 3 months post-
partum with >80% mothers in both groups reporting some breastmilk feeding at 3 months. During 
CTG surveillance there was some transient increase in uterine activity, but no evidence of any fetal 
compromise.  
Conclusions: There was no evidence of harm from advising women with diabetes to express 
breastmilk from 36 weeks' gestation with no increase in rates of NICU admission or preterm delivery. 
Antenatal colostrum expressing was associated with slightly higher rates of breastmilk feeding 
during the first day and throughout hospital admission but this effect was not sustained at 3 months 
post-partum.  
Comment: This high quality randomised controlled trial shows no evidence that antenatal breast 
stimulation leads to earlier onset of labour or higher rates of NICU admission in offspring of women 
with hyperglycaemia. It should be noted that these were mostly women with low risk GDM 
pregnancy and that these data cannot be extrapolated to women with higher risk type 1 and type 2 
diabetes pregnancy. Furthermore women with fetal growth acceleration which is widespread in pre-
gestational diabetes pregnancies were excluded. The authors suggest that future trials of higher risk 
women are required. 
Pregnancy outcome in women with cystic fibrosis-related diabetes 
Acta Obstet Gynecol Scand. 2017 Jun 24. doi: 10.1111/aogs.13185. 
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1Cystic Fibrosis Adult Referral Care Center, Department of Internal Medicine, Civil Hospices of Lyon, 
EA-HESPER7425, University of Lyon, Lyon, France. 2IMER Department, Civil Hospices of Lyon, EA-
HESPER7425, University of Lyon, Lyon, France. 3Biostatistic Department, Civil Hospices of Lyon, 
University of Lyon, CNRS, UMR5558, Laboratory of Biometrics and Evolutionary Biology, Biostatistics-
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Objectives: With advances in care for people with cystic fibrosis (CF), more are surviving into their 
fourth-fifth decades and developing cystic fibrosis related diabetes (CFRD).  The number of 
pregnancies in CF women is also increasing. The aim of this study was to examine the pregnancy 
outcomes of women with CF. 
Methods: A multicentre retrospective cohort study using data from 49 French CF study sites 
between 2001-12. Women were separated into those with and without CFRD and studied for 4 years 
before and up to 2 years following pregnancy. Pregnancies in CF women with lung transplants were 
excluded. Key maternal outcomes were decline in Forced expiratory volume in one-second (FEV1) 
and body mass index (BMI) during follow-up. Other data collected included method of conception, 
mode of delivery, preterm birth (<37 weeks) and neonatal birthweight.   
Results: 294 pregnancies in 232 women with CF were reported; 180 women with 1 pregnancy, 42 
women with 2 pregnancies and 10 with 3 pregnancies, resulting in 234 livebirths. Women were aged 
27 years (range 15-42) and had a BMI of 20 (range 15-34). 80% had pancreatic insufficiency and over 
one third were homozygous for the F508 deletion mutation. Only a small proportion received 
enteral feeding (<4%). There were 29 documented miscarriages and 29 terminations of pregnancy 
(16 therapeutic and 13 for other indications). There were no stillbirths or neonatal deaths. Three 
infants were diagnosed with CF. The overall rate of preterm delivery was 30% with 27% infants 
delivered by caesarean section. The median birthweight was 3000g. Most women (85%) did not have 
CFRD. Among women with diabetes (n=29), maternal age was higher (29 vs 26 years), FEV1 was 
lower (50 vs 67%) and they were more likely to have had a medically assisted conception (54 vs 
34%). No specific data regarding glucose control or diabetes treatment were available. Their BMI 
(19.9 vs 21.1), rate of BMI decline and rate of FEV1 decline was not statistically different to women 
without CFRD. The infants of CFRD mothers were more likely be delivered by caesarean section (48 
vs 21%; p=0.005). Gestational weight gain (GWG) and infant birthweight was comparable between 
women with and women without CFRD; GWG 19.9 vs 21.1 kg, median birthweight 2950 vs 3000g.  
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Conclusions: The pregnancy outcomes of women with CF are generally favourable. CFRD is 
associated with a higher rate of delivery by caesarean section but it is not associated with decline in 
maternal lung function or nutritional status. Early and aggressive treatment of CFRD may have 
minimized the potential negative impact of CFRD on lung function and maternal nutritional status.  
Comment: The number of CF women of reproductive years with good lung function and nutritional 
status is expected to further increase as CFTR modulators are introduced. This study emphasises the 
potential for good pregnancy outcomes in CF women with and without CFRD. More details on the 
glucose control and pregnancy outcomes in women with CFRD is needed. Meanwhile these data will 
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